EYLEA® receives third licence in Europe

EYLEA is an established treatment for other eye conditions that could now offer patients with DMO significant visual benefits, from start of treatment, without the need for strict monthly hospital visits (after an initial five monthly loading doses); potentially reducing the burden of treatment for patients already having to manage their diabetes.(2,3)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Ophthalmology Latest News Source Type: news